Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 1,909 | 1,149 | 223 | - | - | - | |
| Market Cap Growth | 1035.65% | 415.39% | - | - | - | - | |
| Enterprise Value | 1,891 | 1,103 | 28 | - | - | - | |
| Last Close Price | 130.66 | 79.00 | 15.40 | - | - | - | |
| PE Ratio | - | - | 0.13 | - | - | - | |
| PS Ratio | 1468.18 | 883.81 | 1114.65 | - | - | - | |
| PB Ratio | 238.31 | 143.75 | 1.67 | - | - | - | |
| P/TBV Ratio | 238.79 | 143.75 | 1.67 | - | - | - | |
| EV/Sales Ratio | 1454.94 | 848.29 | 142.16 | - | - | - | |
| Debt / Equity Ratio | 13.39 | 13.39 | 0.06 | 4.83 | -0.69 | 1.35 | |
| Net Debt / Equity Ratio | -2.15 | -2.15 | -1.08 | -1.56 | -0.69 | -1.16 | |
| Net Debt / EBITDA Ratio | 0.13 | 0.13 | 0.66 | 0.31 | -0.04 | - | |
| Net Debt / FCF Ratio | 0.13 | 0.13 | 0.73 | 0.34 | -0.05 | - | |
| Asset Turnover | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | 0.05 | |
| Inventory Turnover | 58.29 | 58.29 | 29.93 | 35.84 | - | - | |
| Quick Ratio | 3.68 | 3.68 | 3.76 | 4.95 | 0.01 | 5.85 | |
| Current Ratio | 3.93 | 3.93 | 3.94 | 5.25 | 0.30 | 6.20 | |
| Return on Equity (ROE) | -197.85% | -197.85% | 1905.92% | -1333.38% | -511.61% | -127.91% | |
| Return on Assets (ROA) | -51.58% | -51.58% | -56.86% | -84.42% | -86.27% | -32.53% | |
| Return on Capital Employed (ROCE) | -119.80% | -119.80% | -158.70% | -87.10% | 2794.40% | -59.80% | |
| Earnings Yield | -7.34% | -12.19% | 757.00% | - | - | - | |
| FCF Yield | -6.80% | -11.30% | -88.37% | - | - | - | |
| Buyback Yield / Dilution | -3.36% | -3.36% | -27.17% | 70.62% | -5.52% | -50.47% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.